GET DAILY SIGNALSThermo Fisher Scientific (TMO) Delivers Steady Gains and Raises Full-Year Outlook
Key Takeaways
- Thermo Fisher Scientific (TMO) shares recently traded near $698, up roughly 6% over the trailing month but still well within a broader consolidation range.
- Third-quarter revenue rose 9% to $12.14 billion, with 6% organic growth, while adjusted EPS climbed 15% to $6.68, beating consensus estimates.
- Management raised full-year 2026 guidance to $47.7–$48.2 billion in revenue and $25.13–$25.43 in adjusted EPS, reflecting stronger end-market demand.
- Growth was led by Pharma Services, bioproduction, and electron microscopy, while academic and government demand remained roughly flat.
- The completed Clario acquisition and the microbiology divestiture continue to reshape the company's portfolio and growth profile.
Current Market Snapshot
Thermo Fisher Scientific shares have held in a measured range lately, sitting near the $698 mark after climbing about 6% over the past month. This feels more like a gradual adjustment than a major shift, as investors balance signs of improving demand in life sciences against a valuation that sits above longer-term averages. The recent third-quarter beat and a series of analyst target lifts have provided support, though some remain cautious given the premium multiple. In the life sciences tools space, TMO often serves as a bellwether for biotech funding and pharma R&D trends, so its price action offers a useful read on broader sector sentiment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
Thermo Fisher Scientific ranks among the largest life sciences tools and services companies, with annual revenue topping $45 billion. It serves pharma and biotech firms, hospitals, academic and government labs, and industrial clients across four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Well-known brands include Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon, and PPD.
Its strength lies in a diversified mix of consumables, instruments, and outsourced services that generate recurring revenue across the drug development chain. Scale, global reach, and a disciplined acquisition track record place it alongside peers such as Danaher (DHR) and Agilent Technologies (A) at the heart of the sector. Investors track TMO closely because its results provide a clear signal of underlying demand in biopharma research, diagnostics, and advanced manufacturing.
Recent Developments Driving the Stock
The third-quarter 2026 results, released in late October, served as the main catalyst for the recent price action. Revenue increased 9% to $12.14 billion, including 6% organic growth, while adjusted operating income rose 15% to $2.97 billion and the adjusted operating margin expanded 120 basis points to 24.5%. Adjusted EPS reached $6.68, ahead of estimates, and GAAP diluted EPS grew 9% to $4.64. Management highlighted that the improved end-market trends from the second quarter continued, with high single-digit growth in pharma and biotech plus strength in electron microscopy linked to semiconductor demand.
Along with the results, the company lifted its full-year 2026 outlook to revenue of $47.7–$48.2 billion and adjusted EPS of $25.13–$25.43, pointing to 10%–11% EPS growth. The quarter included roughly $60 million in net tariff refund recoveries, or about $0.15 per adjusted share, part of which was reinvested in AI deployment and capacity. On the strategic side, the microbiology business divestiture closed and integration of the Clario acquisition—a clinical-trials data provider bought earlier in 2026 for $8.875 billion in cash—has progressed smoothly. Several analysts followed up with Buy ratings and price targets in the mid-$700s, though one broker shifted to Hold.
2026 Outlook and Key Areas to Monitor
Looking ahead, the key question centers on whether the biotech funding recovery and stronger pharma-services demand can maintain the momentum seen in the third quarter. Guidance calls for roughly 4% organic growth in the fourth quarter, a step back from the 6% in Q3, partly due to timing of customer activity. The longer-term aim is a return to normalized mid-single-digit or higher growth toward 2027. I’m watching biotech financing trends, academic and government spending, new instrument placements, and Clario integration closely. Macro factors such as interest rates, trade policy, and currency moves also matter for a globally diversified company. The fourth-quarter and full-year report, due in early February, will test how durable the current recovery narrative proves to be. Valuation remains relevant, with the stock still trading at a premium to its historical earnings multiple even as fundamentals strengthen.
Exploring AI Tools for Trading Strategies
In my own research, I often review Tickeron’s Trending AI Robots page to see which AI-driven strategies are performing well across different timeframes and risk levels. It surfaces only the top bots from a larger platform, making it easier to compare approaches without sifting through every option. This helps me test ideas that align with current market conditions before committing capital.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 58 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 135 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 17 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 23 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.901) is normal, around the industry mean (66.911). P/E Ratio (37.525) is within average values for comparable stocks, (2.514). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of analytical and environment monitoring instruments
Industry MedicalSpecialties
Advertisement